Changzhou Qianhong Biopharma Co (SZSE:002550) 3-Year Revenue Growth Rate : 9.90% (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co 3-Year Revenue Growth Rate?

Changzhou Qianhong Biopharma Co's Revenue per Share for the three months ended in Sep. 2023 was ¥0.32.

During the past 12 months, Changzhou Qianhong Biopharma Co's average Revenue per Share Growth Rate was -9.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Changzhou Qianhong Biopharma Co was 58.70% per year. The lowest was -17.50% per year. And the median was 8.80% per year.

Competitive Comparison of Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate falls into.

Changzhou Qianhong Biopharma Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Changzhou Qianhong Biopharma Co (SZSE:002550) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Changzhou Qianhong Biopharma Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Changzhou Qianhong Biopharma Co (SZSE:002550) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022

Website

http://www.qhsh.com.cn

Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Changzhou Qianhong Biopharma Co (SZSE:002550) Headlines

No Headlines